Memphasys Expands South-East Asian Commercial Footprint with Thailand Distribution Agreement
Memphasys Limited (ASX: MEM) has secured an exclusive three-year commercial distribution agreement with IVF Envimed Co., Ltd. for the Felix™ sperm separation system across Thailand, marking another step in the company's international commercialisation strategy. The agreement has a minimum contracted value of approximately A$430,500 over three years and includes an initial order of 100 Felix™ cartridges and three consoles to support pre-launch marketing and clinical education activities ahead of regulatory approval. Revenue generation is expected to commence following Thai FDA approval, which the company anticipates within approximately three to six months. The agreement increases Memphasys' minimum contracted South-East Asian revenue to approximately A$1.0 million across Thailand and Vietnam, while total contracted Felix™ revenues for FY2026 have reached approximately A$3.0 million. IVF Envimed, which has more than 15 years of experience in Thailand's IVF sector, maintains established relationships with all 110 registered IVF clinics nationwide and will manage regulatory approval, distribution and commercial rollout of the Felix™ system.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Memphasys Expands South-East Asian Commercial Footprint with Thailand Distribution Agreement
Memphasys Limited (ASX: MEM) has secured an exclusive three-year commercial distribution agreement with IVF Envimed Co., Ltd. for the Felix™ sperm separation system across Thailand, marking another step in the company's international commercialisation strategy. The agreement has a minimum contracted value of approximately A$430,500 over three years and includes an initial order of 100 Felix™ cartridges and three consoles to support pre-launch marketing and clinical education activities ahead of regulatory approval. Revenue generation is expected to commence following Thai FDA approval, which the company anticipates within approximately three to six months. The agreement increases Memphasys' minimum contracted South-East Asian revenue to approximately A$1.0 million across Thailand and Vietnam, while total contracted Felix™ revenues for FY2026 have reached approximately A$3.0 million. IVF Envimed, which has more than 15 years of experience in Thailand's IVF sector, maintains established relationships with all 110 registered IVF clinics nationwide and will manage regulatory approval, distribution and commercial rollout of the Felix™ system.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au